TY - JOUR
T1 - Accuracy of the Zika IgM antibody capture enzyme-linked immunosorbent assay from the centers for disease control and prevention (CDC Zika MAC-ELISA) for diagnosis of zika virus infection
AU - Portilho, Moyra Machado
AU - Moraes, Laise de
AU - Kikuti, Mariana
AU - Nascimento, Leile Camila Jacob
AU - Reis, Mitermayer Galvão
AU - Boaventura, Viviane Sampaio
AU - Khouri, Ricardo
AU - Ribeiro, Guilherme Sousa
N1 - Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2020/10/18
Y1 - 2020/10/18
N2 - Serological diagnosis of Zika virus (ZIKV) infection is challenging because of antigenic cross-reactivity with dengue virus (DENV). This study evaluated the accuracy of the Zika IgM antibody capture enzyme-linked immunosorbent assay (CDC Zika IgM MAC-ELISA) in differentiating between ZIKV and DENV infections. To determine sensitivity, we used acute- and convalescent-phase sera from 21 patients with RT-PCR-confirmed ZIKV infection. To determine specificity, we used acute- and convalescent-phase sera from 60 RT-PCR-confirmed dengue cases and sera from 23 blood donors. During the acute-phase of the illness, the assay presented a sensitivity of 12.5% (2/16) for samples collected 0–4 days post symptoms onset (DPSO), and of 75.0% (3/4) for samples collected 5–9 DPSO. During the convalescent-phase of the illness, the test sensitivity was 90.9% (10/11), 100% (2/2), and 0% (0/2) for samples obtained 12–102, 258–260, and 722–727 DPSO, respectively. Specificity for acute- and convalescent-phase samples from RT-PCR-confirmed dengue cases was 100% and 93.2%, respectively. Specificity for blood donor samples was 100%. The assay is an accurate method for Zika serological diagnosis and proved to be reliable for use during surveillance and outbreak investigations in settings where ZIKV and DENV cocirculate.
AB - Serological diagnosis of Zika virus (ZIKV) infection is challenging because of antigenic cross-reactivity with dengue virus (DENV). This study evaluated the accuracy of the Zika IgM antibody capture enzyme-linked immunosorbent assay (CDC Zika IgM MAC-ELISA) in differentiating between ZIKV and DENV infections. To determine sensitivity, we used acute- and convalescent-phase sera from 21 patients with RT-PCR-confirmed ZIKV infection. To determine specificity, we used acute- and convalescent-phase sera from 60 RT-PCR-confirmed dengue cases and sera from 23 blood donors. During the acute-phase of the illness, the assay presented a sensitivity of 12.5% (2/16) for samples collected 0–4 days post symptoms onset (DPSO), and of 75.0% (3/4) for samples collected 5–9 DPSO. During the convalescent-phase of the illness, the test sensitivity was 90.9% (10/11), 100% (2/2), and 0% (0/2) for samples obtained 12–102, 258–260, and 722–727 DPSO, respectively. Specificity for acute- and convalescent-phase samples from RT-PCR-confirmed dengue cases was 100% and 93.2%, respectively. Specificity for blood donor samples was 100%. The assay is an accurate method for Zika serological diagnosis and proved to be reliable for use during surveillance and outbreak investigations in settings where ZIKV and DENV cocirculate.
KW - CDC Zika MAC-ELISA
KW - Diagnostic accuracy
KW - Enzyme-linked immunosorbent assay
KW - Sensitivity and specificity
KW - Zika virus
UR - http://www.scopus.com/inward/record.url?scp=85093498486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85093498486&partnerID=8YFLogxK
U2 - 10.3390/diagnostics10100835
DO - 10.3390/diagnostics10100835
M3 - Article
C2 - 33080935
AN - SCOPUS:85093498486
SN - 2075-4418
VL - 10
JO - Diagnostics
JF - Diagnostics
IS - 10
M1 - 835
ER -